<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950050</url>
  </required_header>
  <id_info>
    <org_study_id>0005-18-SZMC</org_study_id>
    <nct_id>NCT03950050</nct_id>
  </id_info>
  <brief_title>Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy</brief_title>
  <official_title>Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ambroxol hydrochloride, an over-the-counter antitussive available in many markets , was
      identified as an interesting pharmacological chaperone. In addition to a mucolytic action,
      ambroxol has antioxidant and anti-inflammatory properties. Importantly, ambroxol therapy was
      found safe when given to pregnant women for prevention of neonatal respiratory distress
      syndrome .

      Thus, ambroxol, an oral available drug on the market, may be a safe option for GD patients
      with potential disease-specific efficacy and should be expanded into a clinical trial using
      higher doses and placebo-controlled design. The investigators propose to start with a phase
      II study for patients with type 1 GD and suboptimal response to ERT. In addition the
      investigators plan to open an international registry of patients with GD currently receiving
      ambroxol (off study).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Description of the Problem:

      Enzyme replacement therapy (ERT) makes a significant impact on the clinical manifestations
      and quality of life of patients with Gaucher disease (GD) . The goals of therapy focus mainly
      on platelets, hemoglobin, spleen, liver, bones and growth parameters for children.

      ERT is mostly effective in patients with type 1 GD; still some patients don't achieve
      normalization or near normalization of the therapeutic targets . Glucosylsphingosine
      (LysoGb1) is the most specific and sensitive, and hence is probably the best currently
      available GD biomarker. A level of LysoGB1 &lt; 140 ng/ml is considered a marker for controlled
      GD (personal communication).

      Patients with GD may also experience chronic fatigue that causes functional disability and
      adversely affects quality of life . The fatigue severity scale (FSS) is a 9-item tool; each
      item is scored on a scale from 1 to 7, with a mean score of 4 or higher considered to
      represent significant fatigue . Patients with GD have improvements in fatigue within 6 months
      of starting ERT, and that it may be among the first symptoms to show significant improvement.
      Using the FSS, no association was identified between fatigue and time on ERT (P = 0.57). In a
      survey of patients with Type 1 GD and physicians, patients ascribed greater importance to
      fatigue than other disease parameters, while physicians placed more emphasis on objective
      measures of visceral and hematologic disease manifestations.

      B. Pharmacological chaperones:

      The underlying pathology in GD is not only due to the lysosomal accumulation of
      glucosylceramide in the tissue macrophages. There is a broader spectrum of lysosomal
      dysfunction and various intracellular and molecular changes that could lead to additional
      disease manifestations that are not affected by ERT. In particular, the retention of the
      mutant glucocerebrosidase within the endoplasmic reticulum (ER) which causes ER stress,
      unfolding protein response (UPR) and early ER associated degradation (ERAD) . These ER
      related changes are the rationale behind the use of pharmacological chaperones which are
      capable of partially removing the misfolded proteins from the ER, thereby relieving ER
      stress, avoiding ERAD and preventing consequent complications . Pharmacological chaperones
      increase glucocerebrosidase activity by stabilizing the enzyme in the lysosome.

      C. The Therapy to be Examined:

      Ambroxol hydrochloride, an over-the-counter antitussive available in many markets, was
      identified as an interesting pharmacological chaperone. In addition to a mucolytic action,
      ambroxol has antioxidant and anti-inflammatory properties . Importantly, ambroxol therapy was
      found safe when given to pregnant women for prevention of neonatal respiratory distress
      syndrome. In skin fibroblasts derived from Type 1 and Type 2 GD patients, ambroxol increases
      both the lysosomal fraction and the enzymatic activity of several mutant glucocerebrosidase
      variants with low toxicity . Incubation of human induced pluripotent stem cell macrophages
      from patients with type I-III GD with ambroxol corrected the abnormal phenotypes of GD
      macrophages. Ambroxol, has a small molecule chaperone, has been shown in healthy nonhuman
      primates to cross the blood-brain barrier, and increase brain glucocerebrosidase activity .
      In Drosophila neuropathic model, ambroxol was show to alleviate the neuronopathic phenotype
      through reducing ER stress ].

      The investigators have performed a pilot study to test the tolerability and efficacy of
      ambroxol as a pharmacological chaperone in patients with symptomatic, type 1 GD who present
      with measurable disease parameters but are not receiving ERT in order to provide proof of
      concept and/or ascertain the suitability of ambroxol for a larger clinical trial [29] . The
      Israeli Ministry of Health Form 29c was employed to prescribe ambroxol for off-label use.
      Twelve patients were dispensed 2 capsules of 75 mg of ambroxol daily for 6 months. One
      patient withdrew because of a hypersensitivity reaction, one because of elective splenectomy.
      No patient experienced clinically relevant deterioration in disease parameters measured. One
      patient achieved a robust response relative to baseline: +16.2% hemoglobin; +32.9% platelets;
      -2.8% liver volume; and -14.4% spleen volume. Three patients elected to continue on ambroxol
      for a further 6 months: hemoglobin levels and liver volumes were relatively stable, but
      platelet counts further increased in the above patient (+52.6% from baseline) and spleen
      volumes decreased further in all three patients (-6.4%, -18.6%, and -23.4% from baseline) .
      More recently, a pilot study of ambroxol was done in five patients with neuronopathic GD in
      combination with enzyme replacement therapy [30]. High-dose oral Ambroxol had good safety and
      tolerability with clinical and laboratory signs of activity.

      Thus, ambroxol, an oral available drug on the market, may be a safe option for GD patients
      with potential disease-specific efficacy and should be expanded into a clinical trial using
      higher doses and placebo-controlled design [31]. The investigators propose to start with a
      phase II study for patients with type 1 GD and suboptimal response to ERT. In addition the
      investigators plan to open an international registry of patients with GD currently receiving
      ambroxol (off study).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The aim of this single arm, phase II study is to evaluate the efficacy and safety of adding ambroxol to patients with type 1 GD and suboptimal response to ERT.
HYPOTHESIS The addition of ambroxol will improve the disease related symptoms and disease impact of patients with GD with suboptimal response to ERT.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelets count</measure>
    <time_frame>12 months.</time_frame>
    <description>Increase in platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bone mineral density evaluated by Dual Energy X-ray Absorptiometry (DEXA)</measure>
    <time_frame>12 months.</time_frame>
    <description>Bone Mineral Densitometry (BMD)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lyso-GB1 biomarker for Gaucher disease</measure>
    <time_frame>12 months</time_frame>
    <description>decrease in Lyso-GB1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes (PRO)</measure>
    <time_frame>12 months</time_frame>
    <description>Improve in PRO from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS)</measure>
    <time_frame>12 months</time_frame>
    <description>Improve in FSS from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gaucher Disease, Type 1</condition>
  <arm_group>
    <arm_group_label>Ambroxol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ambroxol therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.
The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol</intervention_name>
    <description>Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.
The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.</description>
    <arm_group_label>Ambroxol</arm_group_label>
    <other_name>Ambroxol Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        *Adult patients â‰¥ 18 years with type 1 GD and suboptimal response to ERT defined as one or
        more than one of the following: platelet count &lt; 100 x 103/mm3 bone mineral density &lt; -2 T
        score Lyso-GB1 &gt; 200 ng/ml.

        *No change in dose or preparation of ERT in the last 12 months (Except for Naive patients)

        Exclusion Criteria:

          -  Patients with comorbidity that may impact on the primary and/or secondary endpoint.

          -  Pregnant women will be excluded from the study.

          -  Inability to cooperate with the study procedure

          -  Hypersensitivity or any other contraindication listed in the local labeling of
             ambroxol

          -  Refusal of patients to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Zimran</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ari Zimran - Shaare Zedek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joleen Istaiti, B.Sc.</last_name>
    <phone>+97226555143</phone>
    <email>joleenist@szmc.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ari Zimran, MD</last_name>
    <phone>+97226555143</phone>
    <email>azimran@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joleen Istaiti, BS.c</last_name>
      <phone>+97226555143</phone>
      <email>joleenist@szmc.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Ari Zimran, MD</last_name>
      <phone>+97226555143</phone>
      <email>azimran@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Ishay Y, Zimran A, Szer J, Dinur T, Ilan Y, Arkadir D. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. Blood Cells Mol Dis. 2018 Feb;68:117-120. doi: 10.1016/j.bcmd.2016.10.028. Epub 2016 Nov 12. Review.</citation>
    <PMID>27866808</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>September 22, 2019</last_update_submitted>
  <last_update_submitted_qc>September 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambroxol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

